Background
==========

Clear cell renal cell carcinoma (ccRCC) is the most common malignancy in the kidneys, which has increasing incidence and mortality rates worldwide \[[@b1-medscimonit-25-4401]\]. Treatments for localized ccRCC can vary from radio-frequency ablation to partial or radical nephrectomy; however, once RCC progresses to distant metastasis, the curative effect of current targeted drug therapies is limited \[[@b2-medscimonit-25-4401]\]. Additionally, when first diagnosed, approximately 30% patients already have metastasis \[[@b1-medscimonit-25-4401]\]. Therefore, it is urgent to understand the underlying mechanism of metastasis and to identify novel biomarkers with greater prognostic values.

The TNM staging system has been used for over 80 years and is important for estimating the outcome of various cancers; however, it provides an incomplete prognostic value \[[@b3-medscimonit-25-4401]--[@b5-medscimonit-25-4401]\]. Clinical outcomes can differ significantly among patients with the same tumor stage \[[@b6-medscimonit-25-4401]\]. Despite surgical removal of the tumor, a subgroup of patients experience recurrence, indicating that at the time of curative surgery, the metastasis was already present \[[@b7-medscimonit-25-4401]\]. However, no consensus was reached regarding the surveillance protocols of RCC, and no available tumor-associated biomarkers can predict recurrence in patients who may have benefited from earlier therapy \[[@b8-medscimonit-25-4401]\]. Previous studies in colorectal cancer proposed several gene signatures and proved to be useful in predicting prognosis \[[@b9-medscimonit-25-4401]--[@b11-medscimonit-25-4401]\]. In this study, we divided patients from the Cancer Genome Atlas database into a non-metastasis group and a metastasis group in order to screen the differently expressed genes. Furthermore, we constructed a risk scoring system based on upregulated genes involved in metastasis to identify a multi-gene signature for use as an independent predictor for ccRCC.

Material and Methods
====================

Data collection
---------------

The TCGA database contains large cohorts of genomic abnormalities and clinical information across the world, and is publicly available. RNA sequencing counts data from the ccRCC cohort, which consists of 539 tumor samples and 72 normal tissues, were obtained from the TCGA data portal (*<https://tcga-data.nci.nih.gov/tcga/>*). Clinical data pertaining to patients' age, gender, grade, stage, survival and recurred/progressed outcome were also acquired from the TCGA data portal. We divided patients based on N stage and M stage into 2 groups. Patients with both M0 and N0 stage were assigned to the non-metastasis group, whereas M1 and/or N1 patients were assigned to the metastasis group.

Identification of differentially expressed genes (DEGs)
-------------------------------------------------------

We identified the DEGs using the edgeR package, with a cutoff of adj.p-value \<0.05 and a \|logFC\| \>2 \[[@b12-medscimonit-25-4401]\]. DEGs were visualized with volcano plot through the gplots package in R (version 3.5.2).

Enrichment analysis of DEGs
---------------------------

We performed a functional enrichment analysis of the DEGs using DAVID (Database for Annotation, Visualization, and Integrated Discovery) to determine the gene ontology (GO) categories by using cellular component (CC), molecular function (MF), or biological processes (BP), as well as KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway \[[@b13-medscimonit-25-4401]\]. *P*\<0.05 was defined as significant enrichment. An online web tool was used to visualized these processes (*<http://www.ehbio.com/ImageGP/>*).

Construction of PPI network
---------------------------

We used the STRING database to retrieve the protein-protein interaction (PPI) network of DEGs, and we used Cytoscape software to reconstruct and visualize the network \[[@b14-medscimonit-25-4401],[@b15-medscimonit-25-4401]\]. Individual network modules with 10 or more nodes were shown.

Univariate and multivariate Cox analysis to screen the candidate genes
----------------------------------------------------------------------

CcRCC samples were separated into 2 groups according to the median gene expression. Then, age (≤60/\>60), sex (male/female), grade (G1--G2/G3--G4), stage (I--II/III--IV), T stage (T1--T2/T3--T4), N stage (N0/N1), M stage (M0/M1), specific gene, and survival data (time and state) were all included into the Cox regression model to preform univariate and multivariate Cox analysis using SPSS 22.0 (IBM Corporation, Armonk, NY, USA).

Establishment of a prognostic signature based on candidate genes
----------------------------------------------------------------

The stepwise multivariate Cox regression analysis model was constructed based on the candidate genes to extract the mRNA-based model with the best predictive ability. The criteria for inclusion and exclusion was set as *P*\<0.05. Subsequently, the risk score for each patient was computed using the mRNA-based prognostic model as follows: Risk score=expRNA1\*βRNA1+ expRNA2\*βRNA2+expRNA3\*βRNA3+...expRNAn\*βRNAn, where expRNA was the mRNA expression level and βRNA referred to the regression coefficient derived from the multivariate Cox hazards regression analysis. Based on the risk score for each patient, patients from the TCGA database were separated into 2 groups: a low-risk group and a high-risk group. Kaplan-Meier survival analysis was performed to assess differences in overall survival and disease-free time of patients using a log-rank test in GraphPad Prism 7.0. In addition, the receiver operating characteristic (ROC) curve was utilized to evaluate the specificity and sensitivity of the survival and disease-free prediction by the area under the curve using the R package "survivalROC" \[[@b16-medscimonit-25-4401]\]. Heatmaps and clustering were generated based on the ClustVis open web tool \[[@b17-medscimonit-25-4401]\].

Predictive value assessment
---------------------------

To evaluate the clinical value of our risk scoring system, we analyzed the clinical characteristics and risk scores in univariate Cox regression. We included factors with *P*\<0.05 into the multivariate Cox regression analysis model. Then, a P\<0.05 was treated as an independent prognostic factor. Moreover, to assess the relationship between risk level and clinical characteristics, we regrouped the patients based on age, sex, grade, stage, T stage, M stage, N stage, vital status, and risk level. A *P*\<0.05 was considered as statistically significant using the chi-square test.

Results
=======

Differentially expressed genes related to the metastasis of ccRCC
-----------------------------------------------------------------

In this study, we defined M0 and N0 patients as the non-metastasis group (198 cases), while M1 and/or N1 patients (89 cases) were defined as the metastasis group. Altogether, 263 genes were found to be dysregulated according to the cutoff criteria, among which, 101 genes were upregulated and 162 gene were downregulated ([Figure 1](#f1-medscimonit-25-4401){ref-type="fig"}, [Supplementary Table 1](#s1-medscimonit-25-4401){ref-type="supplementary-material"}). Functional enrichment analysis of gene ontology revealed that dysregulated genes were mainly enriched in sequence-specific DNA binding, receptor binding, the extracellular region, the integral component of the plasma membrane, ion transmembrane transport, and insulin receptor signaling pathway. KEGG pathway analysis indicated that genes were primarily enriched in neuroactive ligand-receptor interaction and synaptic vesicle cycle ([Figure 2](#f2-medscimonit-25-4401){ref-type="fig"}). Moreover, the PPI network consisted of 10 modules, which included 255 nodes and 316 edges. The most significant module is shown in [Figure 3](#f3-medscimonit-25-4401){ref-type="fig"}.

Survival-related genes by Cox regression analysis
-------------------------------------------------

To identify key genes that may affect overall survival of patients, we performed Cox proportional hazard regressions analysis on upregulated genes. Twenty key genes were demonstrated to influence overall survival: OTX1, FOXE1, FAM83A, HMGA2, KRT6A, DPYSL5, ANXA8, MATN4, ROS1, CSMD3, MAGEC3, AMER2, CPLX2, PI3, KRT13, ERVV-2, ANKFN1, VTN, NFE4, and ZNF114 ([Figure 4](#f4-medscimonit-25-4401){ref-type="fig"}).

Construction of a risk scoring system based on candidate genes
--------------------------------------------------------------

For the purpose of extracting a signature that possesses the best predictive efficacy, 20 key genes were subjected to the stepwise multivariate Cox regression model. Results from the model revealed a total of 5 genes that proved to be significant survival predictors. The related information of these 5 genes is shown in [Table 1](#t1-medscimonit-25-4401){ref-type="table"}. Subsequently, the risk score for each patient was computed as follows: expOTX1\*0.725+expMATN4\*0.473+expPI3\*0.548+expERVV-2\*0.458+expNFE4\*0.410. According to the median risk score, we assigned these scores to the low- or high-risk group. Overall survival analysis showed that the low-risk group had better prognoses compared with the high-risk group ([Figure 5A](#f5-medscimonit-25-4401){ref-type="fig"}). The prognostic ability of the 5-gene signature was assessed by the AUC value of the ROC curve. The AUC was 0.687 for 3-year and 0.695 for 5-year overall survival, indicating a good performance of the 5-gene signature ([Figure 5C, 5E](#f5-medscimonit-25-4401){ref-type="fig"}). Risk scores in the low-risk group ranged from 0 to 0.215232506445 and ranged from 0.215490360701 to 360.615372760823 in the high-risk group ([Figure 5G](#f5-medscimonit-25-4401){ref-type="fig"}). Disease-free survival analysis revealed a significant difference between the 2 groups, with the low-risk group having a longer disease-free time ([Figure 5B](#f5-medscimonit-25-4401){ref-type="fig"}). In the ROC curve, the AUC for 3-year disease-free survival was 0.674 and 0.681 for 5-year disease-free survival ([Figure 5D, 5F](#f5-medscimonit-25-4401){ref-type="fig"}). Risk scores in the low-risk group ranged from 0 to 0.187870897657 and from 0.194574172497 to 360.615372760823 in the high-risk group ([Figure 5H](#f5-medscimonit-25-4401){ref-type="fig"}). [Figure 6](#f6-medscimonit-25-4401){ref-type="fig"} shows the expression patterns of all the 5 genes in the 2 groups. The expression of OTX1, MATN4, and PI3 were significantly higher in the high-risk group in the 2 cohorts ([Figure 7](#f7-medscimonit-25-4401){ref-type="fig"}).

Assessment of gene signature prognostic value
---------------------------------------------

Univariate Cox regression analysis of the prognostic power of our risk scoring system showed that age, grade, stage, T stage, N stage, M stage, and risk level were all indicators of poor outcome. Then, these 7 indexes were entered into the multivariate Cox regression model, showing that risk level could be treated as an independent prognostic factor ([Table 2](#t2-medscimonit-25-4401){ref-type="table"}). Furthermore, as is shown in [Table 3](#t3-medscimonit-25-4401){ref-type="table"}, based on the chi-square test, risk level was significantly correlated with sex, grade, tumor stage, T stage, N stage, M stage, and vital status. Collectively, our results demonstrate that our 5-gene signature is a robust tool for use in predicting prognosis and recurrence.

Discussion
==========

CcRCC has been shown to display distinct variability in clinical outcome, possibly due to the intrinsic molecular heterogeneity, which remains unclear, especially with regard to the mechanism of distant metastasis \[[@b18-medscimonit-25-4401]\]. Moreover, the clinically available parameters, such as TNM stage and Fuhrman grade, are indispensable for prognostic prediction \[[@b19-medscimonit-25-4401]\]. Nevertheless, there remains an urgent need to detect prognostic biomarkers due to the high heterogeneity in ccRCC.

In the current study, we performed bioinformatic analysis between the non-metastasis and metastasis ccRCC group to identify genes involved in metastasis. As a result, we found that 263 genes were dysregulated; functional enrichment analysis of these genes revealed that dysregulated genes were primarily enriched in sequence-specific DNA binding, receptor binding, extracellular region, integral component of plasma membrane, ion transmembrane transport, insulin receptor signaling pathway, neuroactive ligand-receptor interaction, and synaptic vesicle cycle. Most importantly, we identified a 5-gene panel signature (OTX1, MATN4, PI3, ERVV-2, and NFE4) after the Cox proportional hazards regression analysis. Then, a risk score was acquired by combing the 5 genes. Recently, Wei et al. also identified key genes involved in the metastasis of ccRCC using similar bioinformatics methods \[[@b20-medscimonit-25-4401]\]. However, in our study, we make our inclusion criteria clear with regard to the metastasis and non-metastasis groups. Moreover, we calculated each patient's risk score based on the 5-gene signature. The 5-gene signature could independently predict overall survival for ccRCC patients, demonstrating that this signature might be useful in clinical practice.

OTX1 encodes a member of the Bicoid sub-family of homeodomain-containing transcription factor, which may play a role in sensory and brain organ development. It has been described as a vital molecule for axon refinement \[[@b21-medscimonit-25-4401]\]. Terrinoni et al. demonstrated that the p53 protein can directly induce OTX1 expression by acting on its promoter in breast cancer, and Figueira-Muoio et al. revealed that the OTX pathway is important in medulloblastomas development \[[@b22-medscimonit-25-4401],[@b23-medscimonit-25-4401]\]. OTX1 was also found to promote colorectal cancer progression *in vitro* through epithelial-mesenchymal transition and hepatocellular carcinoma progression by regulation of the ERK/MAPK pathway \[[@b24-medscimonit-25-4401],[@b25-medscimonit-25-4401]\]. In bladder cancer, OTX1 combined with FGFR3 and TERT can function as a surveillance biomarker \[[@b26-medscimonit-25-4401]\]. However, the role of OTX1 in ccRCC is still unknown. PI3, also called elafin, encodes an elastase-specific inhibitor that functions as an antimicrobial peptide \[[@b27-medscimonit-25-4401],[@b28-medscimonit-25-4401]\]. Caruso et al. demonstrated that elafin predicts poor outcome in ovarian and breast cancer patients, and it may play a role in tumor dormancy; moreover, it has been shown that elafin is an important therapeutic target for breast and ovarian carcinoma \[[@b29-medscimonit-25-4401]--[@b31-medscimonit-25-4401]\]. MATN4, a member of the von Willebrand factor A domain-containing protein family, has not been widely studied in cancer to date \[[@b32-medscimonit-25-4401]\]. A study showed that under acute stress, CXCR4 and MATN4 are involved in the regulation of hematopoietic stem cells proliferation and expansion \[[@b33-medscimonit-25-4401]\]. ERVV-2 is functionally important in reproduction, and NFE4 is involved in preferential expression of the gamma-globin genes in fetal erythroid cells \[[@b34-medscimonit-25-4401],[@b35-medscimonit-25-4401]\]. These 2 genes have not been well defined in cancer biology, particularly in ccRCC.

In summary, our study used an integrated analysis to identify differentially expressed genes that participate in metastasis of ccRCC. Furthermore, we constructed a 5-gene signature with a quantitative index that exhibited an independent prognostic value. In the future, this 5-gene signature may be used to identify patients who need regional lymph node dissection during radical nephrectomy \[[@b36-medscimonit-25-4401]\]. Since these 5 genes are correlated with poor outcome, they might be therapeutic targets for ccRCC. However, *in vivo* and *in vitro* studies are still needed to reveal the biological functions of these predictive mRNAs in ccRCC.

Conclusions
===========

We identified differentially expressed genes that may participate in the metastasis of ccRCC. More importantly, we established a predictive signature based on the expression of OTX1, MATN4, PI3, ERVV-2, and NFE4, which could serve as significant progressive and prognostic biomarkers for ccRCC.

Supplementary Table 1
=====================

###### 

Differentially expressed genes involved in metastasis in ccRCC.

  Genes       Log FC         Genes        Log FC         Genes       Log FC
  ----------- -------------- ------------ -------------- ----------- --------------
  PRSS38      7.293012973    PASD1        5.849055467    BAAT        4.972016934
  KCNE5       4.734843904    NFE4         4.607079054    ALPG        4.569998517
  FDCSP       4.526032273    CABP2        4.453865694    OLFM4       4.268762733
  GAGE1       4.26812475     LHX3         4.065474738    KRT13       4.019547465
  CRABP1      3.807319872    SOHLH1       3.801178392    CACNG6      3.763439672
  VSTM2B      3.632937049    ANXA8        3.591407826    H2BFM       3.555425223
  AMER3       3.524447368    MAGEC2       3.503241713    ERVV--2     3.464200342
  CPLX2       3.401097143    GABRA3       3.388167297    RORB        3.361591792
  MUC16       3.298663286    MARCOL       3.250302515    ZDHHC22     3.239809076
  IGFL3       3.196619228    MTRNR2L6     3.179688152    C1orf94     3.13666645
  PI3         3.126993299    CSMD3        3.047313412    ISL1        2.981373363
  SP8         2.966745906    PNLIP        2.924034656    AMER2       2.904669856
  TLX3        2.903886912    PDX1         2.882186281    DPYSL5      2.869458768
  LCN15       2.843884331    VTN          2.819241353    ZPLD1       2.795929776
  ISX         2.795438433    EPPIN        2.734479911    ALPP        2.699771711
  PTPRZ1      2.695461275    INSL4        2.691308392    CHAT        2.659157612
  MAGEC3      2.626652586    DAB1         2.581804555    RDH8        2.559245587
  XKR7        2.556307418    CIDEC        2.535297601    ROS1        2.520534946
  CSN3        2.519649538    VSTM2L       2.490355446    HTR1D       2.489417462
  FAM83A      2.455106896    S100A7       2.43745305     HMGA2       2.423695315
  ANKFN1      2.408489181    UBE2U        2.401187787    TRPV5       2.378341308
  LCE1C       2.377491995    DRGX         2.375422577    SLC18A3     2.366620248
  KLF17       2.362440353    ZIC2         2.35428125     SPACA3      2.348805744
  FCRL4       2.346660183    CRP          2.332869284    SPANXB1     2.326683931
  UTS2R       2.314650465    MATN4        2.311903817    ZNF114      2.30971043
  ADIPOQ      2.296860368    KISS1        2.295428739    LIN28B      2.291059085
  ANXA8L1     2.248521884    MAGEB1       2.242953797    SPANXN3     2.242130571
  IL22RA2     2.240150546    C1QL2        2.209979502    AGBL1       2.206686442
  TLX2        2.202836841    RLBP1        2.159036842    NPPB        2.154907807
  HTR5A       2.149124359    SERPINB3     2.14782693     SBSN        2.1417701
  SPINK6      2.114686901    FOXE1        2.096651213    GNG13       2.082021332
  ALOXE3      2.054881574    RTP3         2.051444937    OTX1        2.040341385
  HMX2        2.030173909    KIRREL3      2.025763852    DMRTA2      2.018437908
  KRT6A       2.006147507    IRS4         −7.069279584   AQP6        −6.952633679
  LY6L        −6.466292518   HHATL        −6.178662879   CRISP3      −5.942489086
  PAGE5       −5.566923649   HBG1         −5.565412617   SFTPB       −5.46165805
  MDFIC2      −4.7346839     MAGEA11      −4.702227866   CCKAR       −4.620218512
  NTSR2       −4.412067953   LRRTM1       −4.295989741   CLDN8       −4.291159779
  PAGE2B      −4.290100156   DCAF4L2      −4.285297367   CHRM1       −4.203135741
  FEZF2       −4.181641013   SERTM2       −4.084855062   PSG4        −4.069117346
  DEFB125     −4.034642804   ATP6V0A4     −4.03380667    ATP6V1G3    −3.918376267
  FXYD4       −3.882031698   C10orf71     −3.845620551   ST8SIA3     −3.817050292
  TTR         −3.8141048     PAGE4        −3.813169574   FGF9        −3.781764959
  POU3F4      −3.771004791   ATP6V0D2     −3.753224136   PSG9        −3.751868431
  SPOCK3      −3.749385525   TMEM213      −3.705206888   KBTBD12     −3.684155012
  KRTAP5--8   −3.632121999   PIP          −3.541015006   TMEM215     −3.537175656
  RHBG        −3.513276723   CTNNA2       −3.497574449   GJD2        −3.465274322
  GLB1L3      −3.462356811   SLC4A1       −3.459997603   NUPR2       −3.451627461
  HBG2        −3.360260797   NR5A1        −3.354792948   VWA5B1      −3.340662569
  MLANA       −3.311141752   OMG          −3.302149224   BSND        −3.275017729
  AQP10       −3.234439151   FER1L6       −3.223091448   SLC26A7     −3.196657291
  KLK1        −3.168181356   ATP6V1B1     −3.166112958   RHCG        −3.157008772
  FGL1        −3.146889407   TNNT3        −3.130099704   SLC24A2     −3.090435759
  PLK5        −3.073715835   PSG5         −3.063389834   TYR         −3.036736515
  CD177       −2.967875945   CDH7         −2.947214145   XAGE5       −2.941242246
  AQP5        −2.928574991   LGI1         −2.920563422   SCRT1       −2.915273241
  LCN1        −2.897125323   CRISP2       −2.891236689   CGA         −2.880719932
  FOXI1       −2.856870004   SLC4A9       −2.85058536    GREM2       −2.846325204
  ADAM7       −2.823853478   MYMX         −2.780243665   FOXI2       −2.747040565
  BPIFA2      −2.744920257   NXPH2        −2.73264296    FAM24B      −2.005641145
  CLCNKB      −2.711841094   DNTT         −2.703518233   FRG2C       −2.696015544
  TMEM61      −2.688842068   CASP14       −2.687885646   GIMD1       −2.686569536
  LHFPL4      −2.682599598   ADCYAP1      −2.68255206    TBATA       −2.65671051
  DMRT2       −2.645831657   MCCD1        −2.625093054   PAGE2       −2.615268476
  GPRC6A      −2.613101443   WFIKKN2      −2.598374715   UGT2B4      −2.586510771
  IGF2        −2.56153826    KERA         −2.560942199   FRG2B       −2.549870167
  SLC7A13     −2.544471449   MOG          −2.537312543   ASCL4       −2.534282307
  C11orf53    −2.519948822   PSCA         −2.507368106   GCGR        −2.506059534
  PLA2G4F     −2.494234559   DAZ1         −2.461947613   NKX6--1     −2.457759032
  RHAG        −2.444447278   LUZP2        −2.426420149   HBM         −2.424034763
  NMRK2       −2.412559163   TRIM50       −2.4050669     LRRC52      −2.396507205
  GRIK1       −2.380726671   CRYAA        −2.361368316   ADRB1       −2.352091261
  AHSP        −2.350914787   ASB5         −2.345814708   CNMD        −2.339953179
  GGTLC3      −2.332560999   GCG          −2.325940672   PSG8        −2.303814006
  STAP1       −2.295027287   RGS8         −2.290434876   STAC2       −2.269340054
  CYP1A1      −2.246907308   KRTAP5--3    −2.240169508   HBD         −2.234219697
  RBBP8NL     −2.232288152   UGT2B28      −2.229968426   ATP13A5     −2.22816884
  SMOC1       −2.226575753   DEFA4        −2.194637278   FRMD7       −2.190289838
  CA1         −2.182904697   CLNK         −2.179307919   SRARP       −2.162262658
  ERP27       −2.157025947   KLK4         −2.152704502   FAM133A     −2.145658322
  PNMT        −2.136928193   CEACAM7      −2.131707182   NRK         −2.11265576
  SMIM5       −2.105569769   DEFA3        −2.104237638   TDGF1       −2.101766107
  ADGRF1      −2.098885814   GRM1         −2.096205239   HEMGN       −2.091490619
  UGT1A4      −2.087390147   AL445989.1   −2.918112259   PRG4        −2.083544157
  ABCB5       −2.082109144   PGPEP1L      −2.077264255   PCP4        −2.063618468
  HAO1        −2.062354203   HSPB3        −2.051568162   MYH8        −2.04723169
  THBS4       −2.085595685   AL035425.2   −4.867341747   C20orf141   2.010402307
  TMPRSS11E   −4.867341747   HEPACAM2     −2.731391743               
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![The volcano plot for DEGs related to metastasis. The x-axis is -log10(FDR) and the y-axis is logFC. The red dots represent upregulated genes and green dots represent downregulated genes.](medscimonit-25-4401-g001){#f1-medscimonit-25-4401}

![Go term and KEGG pathway analysis for DEGs. (**A**) Top 10 molecular function (MF) processes. (**B**) Cellular component (CC). (**C**) Top 10 biological processes (BP). (**D**) KEGG pathway analysis.](medscimonit-25-4401-g002){#f2-medscimonit-25-4401}

![The most significant module. The color and the size of a node indicates the number of proteins interacting with the designated protein.](medscimonit-25-4401-g003){#f3-medscimonit-25-4401}

![(**A--T**) Survival-related upregulated genes. Kaplan-Meier survival curves were generated for genes with P\<0.05 in multivariate Cox regression analysis.](medscimonit-25-4401-g004){#f4-medscimonit-25-4401}

![The 5-gene predictive signature in ccRCC. (**A**) Kaplan-Meier curve of OS in the low- and high-risk groups. (**B**) Kaplan-Meier curve of DFS in the low- and high-risk groups. (**C**) ROC curve for the 3-year survival prediction by the 5-gene signature. (**D**) ROC curve for the 3-year disease-free survival prediction by the 5-gene signature. (**E**) ROC curve for the 5-year survival prediction. (**F**) ROC curve for the 5-year disease-free survival prediction. (**G**) Risk scores distribution among OS cohort. (**H**) Risk scores distribution among DFS cohort.](medscimonit-25-4401-g005){#f5-medscimonit-25-4401}

![Expression pattern of the 5-gene signature in OS and DFS cohort. (**A--C**). In the OS cohort, the expression levels of OTX1, MATN4, and PI3 were significantly higher in the high-risk group. (**D--F**). In the DFS cohort, the expression levels of OTX1, MATN4, and PI3 were significantly higher in the high-risk group.](medscimonit-25-4401-g006){#f6-medscimonit-25-4401}

![Heatmap of the 5 genes. (**A**) Heatmap of the OS cohort. (**B**) Heatmap of the DFS cohort. Red indicates the high-risk group, while blue indicates the low-risk group.](medscimonit-25-4401-g007){#f7-medscimonit-25-4401}

###### 

Overall information of 5 genes constructing the prognostic signature.

  Gene     Gene name                                Gene type        Hazard ratio   Coefficient   P value
  -------- ---------------------------------------- ---------------- -------------- ------------- ----------
  OTX1     Orthodenticle Homeobox 1                 Protein-coding   2.064          0.725         \<0.0001
  MATN4    Matrilin 4                               Protein-coding   1.605          0.473         0.007
  PI3      Peptidase Inhibitor 3                    Protein-coding   1.73           0.548         0.002
  ERVV-2   Endogenous Retrovirus Group V Member 2   Protein-coding   1.581          0.458         0.009
  NFE4     Nuclear Factor, Erythroid 4              Protein-coding   1.506          0.41          0.015

###### 

Univariate and multivariate analysis of risk level and patient survival.

  Variables          Univariate analysis   Multivariate analysis                                     
  ------------------ --------------------- ----------------------- ---------- ------- -------------- --------
  Overall survival                                                                                   
                                                                                                     
  Age (years)                                                                                        
   ≤60 (257)         1.683                 1.228--2.306            0.001      1.540   1.122--2.114   0.007
   \>60 (246)                                                                                        
                                                                                                     
  Sex                                                                                                
   Male (325)                                                      0.791                             
   Female (178)                                                                                      
                                                                                                     
  Stage                                                                                              
   I+II (303)        4.313                 3.092--6.015            \<0.0001   2.511   1.256--5.019   0.009
   III+IV (200)                                                                                      
                                                                                                     
  T stage                                                                                            
   T1--T2 (321)      3.482                 2.534--4.785            \<0.0001                          0.681
   T3--T4 (182)                                                                                      
                                                                                                     
  N stage                                                                                            
   N0 (487)          3.925                 2.124--7.255            \<0.0001                          0.093
   N1 (16)                                                                                           
                                                                                                     
  M stage                                                                                            
   M0 (425)          4.572                 3.21--6.294             \<0.0001   2.202   1.500--3.232   0.0001
   M1 (78)                                                                                           
                                                                                                     
  Grade                                                                                              
   G1--G2 (232)      2.644                 1.860--3.759            \<0.0001                          0.051
   G3--G4 (271)                                                                                      
                                                                                                     
  Risk level                                                                                         
   Low risk (251)    2.592                 1.859--3.612            \<0.0001   1.779   1.251--2.530   0.001
   High risk (252)                                                                                   

HR estimated from Cox proportional hazard regression model; multivariate models were adjusted for age, grade, T, N, M, and stage.

HR -- hazard ratio; CI -- confidence interval.

###### 

Relationship between clinical parameters and risk level.

  Subgroup       High risk      Low risk       Total   P value[\*](#tfn3-medscimonit-25-4401){ref-type="table-fn"}
  -------------- -------------- -------------- ------- -------------------------------------------------------------
  Age                                                  0.503
   ≤60           125 (24.85%)   132 (26.24%)   257     
   \>60          127 (25.25%)   119 (23.66%)   246     
  Sex                                                  0.008
   Male          180 (35.79%)   151 (30.01%)   331     
   Female        72 (14.31%)    100 (19.88%)   172     
  Grade                                                \<0.0001
   G1--G2        86 (17.10%)    146 (29.03%)   232     
   G3--G4        166 (33.00%)   105 (20.87%)   271     
  Stage                                                \<0.0001
   I+II          119 (23.66%)   184 (36.58%)   303     
   III+IV        133 (26.44%)   67 (13.32%)    200     
  T stage                                              \<0.0001
   T1--T2        132 (26.24%)   189 (37.57%)   321     
   T3--T4        120 (23.86%)   62 (12.33%)    182     
  N stage                                              \<0.0001
   N0            111 (45.87%)   114 (47.11%)   225     
   N1            16 (6.61%)     1 (0.41%)      17      
  M stage                                              \<0.0001
   M0            178 (37.47%)   219 (46.11%)   397     
   M1            57 (12.00%)    21 (4.42%)     78      
  Vital status                                         \<0.0001
   Alive         141 (28.03%)   200 (39.76%)   341     
   Dead          111 (22.07%)   51 (10.14%)    162     

Chi-square test was used.
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